Home › Funds › Merck & Co., Inc. › VRDN
Merck & Co., Inc. position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
Merck & Co., Inc. reported holding 93,414 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.9M, representing 0.23% of its reported portfolio and ranking #10 among its reported holdings. Merck & Co., Inc. has disclosed VRDN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s VRDN position evolved
Merck & Co., Inc. first disclosed a stake in VRDN in Q4 2024 at 93,414 shares (US$1.8M). The position peaked in Q4 2025 at 93,414 shares, worth US$2.9M. Across 8 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 93,414 shares valued at US$1.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 93.41K | $1.79M | New |
| Q1 2025 | 93.41K | $1.26M | Hold |
| Q2 2025 | 93.41K | $1.31M | Hold |
| Q3 2025 | 93.41K | $2.02M | Hold |
| Q4 2025 | 93.41K | $2.91M | Hold |
| Q1 2026 | 93.41K | $1.83M | Hold |
| Q2 2026 | 93.41K | $1.72M | Hold |
| Q3 2026 | 93.41K | $1.92M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Bellevue Group AG 6.73M sh · $123.67M · Q2 2026
- Paradigm Biocapital Advisors LP 6.72M sh · $123.52M · Q2 2026
- Kynam Capital Management, LP 6.45M sh · $118.56M · Q2 2026
- Fairmount Funds Management LLC 5.09M sh · $93.52M · Q2 2026
- Deep Track Capital, LP 3.59M sh · $66.00M · Q2 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $59.85M · Q2 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $45.92M · Q2 2026
- BAKER BROS. ADVISORS LP 2.38M sh · $43.78M · Q2 2026
- Caligan Partners LP 2.19M sh · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M sh · $39.22M · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held VRDN?
Merck & Co., Inc. has disclosed VRDN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Merck & Co., Inc.'s current position in VRDN?
As of Q3 2026, Merck & Co., Inc. holds 93.41K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $1.92M, representing 0.23% of its reported portfolio and ranking #10.
Has Merck & Co., Inc. been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in VRDN. The position peaked in Q4 2025 at 93.41K shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.